Skip to main content
    S

    Sarepta Therapeutics Inc (SRPT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.77
    -0.36 (-2.38%)

    Market Cap: $1.72B

    Last updated: Nov 17, 2026 at 4:38 PM ET

    Sarepta Therapeutics Inc (SRPT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Sarepta Therapeutics (SRPT) has a market cap of $1.72B and an enterprise value of $2.11B. Its share count is up 5.68% from a year earlier. Revenue fell 18.95% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 22.32% above the market cap, as debt exceeds cash.

    Market Cap$1.72B
    Enterprise Value$2.11B
    Latest price (Nov 17, 2026)$14.77

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.47% in the quarter ended Sep 30, 2026 and grew 5.38% a year over 2 years.

    Shares Outstanding105.93M
    Shares Change (YoY)+5.68%
    Shares Change (QoQ)+0.47%
    Share Count Growth (2Y CAGR)+5.38%

    Valuation Ratios

    Sales and book value multiples are 0.8x and 1.0x. Its year-end P/S ranged from 1.0x to 276.4x from 2016 to 2025.

    Forward P/E5.5x
    P/S Ratio0.8x
    Forward P/S0.9x
    P/B Ratio1.0x
    P/FCF Ratio8.9x
    P/OCF Ratio9.3x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 11.0x free cash flow.

    EV / Earnings142.8x
    EV / Sales1.1x
    EV / FCF11.0x

    Price Statistics

    The stock is down 21.48% over 52 weeks and trades 19.38% below its 50-day average.

    Beta (1Y)1.74
    52-Week Change-21.48%
    1-Month Change-16.69%
    3-Month Change-25.14%
    6-Month Change-11.24%
    5-Year Change-76.47%
    10-Year Change-52.55%
    Total Return (1Y)-21.48%
    Total Return (3Y CAGR)-43.78%
    Total Return (5Y CAGR)-28.85%
    Return vs SPY (1Y)-26.87%
    Max Drawdown (1Y)-38.02%
    Max Drawdown (3Y)-92.72%
    Sharpe Ratio (1Y)-0.24
    Correlation with SPY (1Y)0.35
    50-Day Average$18.32
    200-Day Average$18.46
    52-Week Range$14.68 to $24.68
    RSI (14 Days)31.2
    Average Volume (20 Days)1.82M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.46x current liabilities, and total debt is 0.56x shareholder equity.

    Current Ratio3.46x
    Quick Ratio2.13x
    Debt / Equity0.56x
    Debt / FCF4.86x

    Returns and Efficiency

    Return on invested capital is -3.22% over the last 12 months, against a 5-year average of -24.03%.

    Return on Equity (ROE)0.97%
    Return on Assets (ROA)0.47%
    Return on Invested Capital (ROIC)-3.22%
    ROE (5Y Average)-67.48%
    ROA (5Y Average)-13.51%
    ROIC (5Y Average)-24.03%
    Asset Turnover0.59x
    Receivables Turnover5.24x

    Taxes

    Income tax took 60.49% of pretax income over the last 12 months.

    Income Tax (TTM)$22.60M
    Effective Tax Rate60.49%

    Scores

    SRPT has an Altman Z-Score of -0.34, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-0.34
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $1.96B over the last 12 months.

    Revenue$1.96B
    Revenue Growth (YoY)-18.95%
    Gross Profit$1.96B
    Operating Income-$48.90M
    Pretax Income$37.36M
    Net Income$14.76M
    Reported EPS (TTM)-$0.10

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 48.26% of the $3.17B in total assets.

    Cash and Equivalents$472.76M
    Total Debt$857.36M
    Net Debt$384.60M
    Net Debt Per Share$3.63
    Working Capital$1.62B
    Shareholder Equity$1.53B
    Book Value Per Share$14.43
    Total Assets$3.17B
    Total Liabilities$1.64B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $9.16M of capital spending, operating cash flow left $176.40M of free cash flow.

    Operating Cash Flow$185.56M
    Capital Expenditures$9.16M
    Free Cash Flow$176.40M
    FCF Per Share$1.67
    Depreciation and Amortization$32.16M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2.50%, against a 5-year average of -32.97%.

    Gross Margin100.00%
    Operating Margin-2.50%
    Pretax Margin1.91%
    Net Margin0.75%
    FCF Margin9.02%
    Operating Margin (5Y Average)-32.97%
    Net Margin (5Y Average)-39.65%

    Growth

    Revenue grew 33.06% a year over 3 years.

    Revenue Growth (3Y CAGR)+33.06%
    Revenue Growth (5Y CAGR)+32.41%
    Book Value Per Share Growth (2Y CAGR)+15.65%
    Tangible Book Per Share Growth (2Y CAGR)+15.65%

    Revenue and profit by year

    Dividends and Yields

    SRPT does not pay a dividend. Its free cash flow yield is 11.27%.

    FCF Yield11.27%
    Buyback Yield0.01%
    Shareholder Yield0.01%

    Stock Splits

    The last split was a 1-for-6 reverse split on Jul 12, 2012.

    Last Split DateJul 12, 2012
    Split TypeReverse split
    Split Ratio1:6

    Peer Position

    Against 9 similar companies, SRPT has the lowest P/S.

    P/S Ratio0.8x vs 21.6x median
    ROIC-3.22% vs -65.35% median
    Revenue Growth (Trailing 4 Quarters, YoY)-18.95% vs +56.18% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -20.66% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-20.66%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About SRPT

    What is SRPT's market cap?

    Sarepta Therapeutics has a market cap of $1.72B. Its enterprise value, which adds debt and subtracts cash, is $2.11B.

    How many shares of SRPT are outstanding?

    Sarepta Therapeutics has 105.93M shares outstanding. The count is up 5.68% from a year earlier.

    Does SRPT pay a dividend?

    No. Sarepta Therapeutics does not pay a dividend.

    How much debt does SRPT have?

    Sarepta Therapeutics has $857.36M of total debt and $472.76M of cash and equivalents, a net debt position of $384.60M.